| scholarly article | Q13442814 |
| P356 | DOI | 10.1681/ASN.2004080632 |
| P698 | PubMed publication ID | 15872078 |
| P2093 | author name string | Dick de Zeeuw | |
| Shahnaz Shahinfar | |||
| Zhongxin Zhang | |||
| Barry M Brenner | |||
| Tania Z Dickson | |||
| William F Keane | |||
| Carl Erik Mogensen | |||
| Steven M Snapinn | |||
| Gilbert W Gleim | |||
| Denise Ramjit | |||
| P433 | issue | 6 | |
| P921 | main subject | losartan | Q410074 |
| P304 | page(s) | 1775-1780 | |
| P577 | publication date | 2005-05-04 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study | |
| P478 | volume | 16 |
| Q87237610 | Accurate estimation of protein/creatinine ratio on urine sample in CKD patients |
| Q36026304 | Antioxidants in kidney diseases: the impact of bardoxolone methyl |
| Q89398963 | Chronic kidney disease is associated with carotid atherosclerosis and symptomatic ischaemic stroke |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q35986524 | Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. |
| Q41879242 | Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q37892908 | Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? |
| Q36666997 | Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention |
| Q34156850 | Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis |
| Q80295400 | Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis |
| Q36428522 | Losartan: lessons learned from the RENAAL study |
| Q44717786 | Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). |
| Q35896622 | Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort |
| Q44248315 | Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. |
| Q79157988 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study |
| Q36677647 | Role of remission clinics in the longitudinal treatment of CKD. |
| Q36175799 | Role of upstream stimulatory factor 2 in diabetic nephropathy |
| Q39720848 | Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients |
| Q37741783 | The RAAS in the pathogenesis and treatment of diabetic nephropathy |
| Q38845590 | The next generation of therapeutics for chronic kidney disease |
Search more.